Últimas noticias sobre Danaher (NYSE:DHR) Bolsa

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Long Ideas

News

Markets

Media

Trading Ideas

ATEN

FSLY

IESC

Jim Cramer analiza el rendimiento de varias acciones estadounidenses y comparte sus recomendaciones clave. ¿Cuáles destacan y cuáles evitar?

Cramer respalda NextEra Energy (NEE) y descarta otras acciones: ¿cuáles tienen más potencial?

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

Danaher 's Beckman Coulter Announces FDA Clearance Of Its DxC 500i Clinical Analyzer

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 2.73% on an annualized basis producing an average annual return of 13.62%. Currently, Danaher has a market capitalization of $149.62 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $356.90 today based on a price of $209.35 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740603615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Dan&nbsp;Loeb‘s&nbsp;Third Point LLC, which has a varied mix of stock from across the sectors, did some major portfolio restructuring in the <a target="_blank" href="https://www.benzinga.com/topic/dan-loeb" rel="noreferrer noopener">last quarter of 2024</a>.
According to recent 13F filings,&nbsp;reflecting his holding as of Dec. 31, 2024, Loeb slashed a stake in the major Life Sciences Tools &amp; Services company Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">to </a>1,900,000 from 1,950,000 shares <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624005927/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">in </a>the third quarter of 2024, a decline of around 2.5%.
Notably, the investor has been cutting stake in Danaher in the last couple of quarters. Earlier, he held 2,050,000 shares <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624004004/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">as </a>of second quarter of 2024 and 2,450,000 shares as <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514623004511/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">of </a>third quarter of 2023.
Instead, the investor acquired a stake in Danaher&#8217;s major peer Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), attaining 350,000 shares in the fourth quarter 2024.
Read: <a target="_blank" href="https://www.benzinga.com/25/02/43861240/repligens-q4-earnings-beat-2025-guidance-highlights-market-growth" rel="noreferrer noopener">Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook</a>
DHR Major Events:
<ul>
<li>In January, the company reported weaker-than-expected fourth-quarter earnings, with adjusted earnings per share of $2.14 missing the street view of $2.16 and sales of $6.54 billion (+2%), beating the analyst <a href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" target="_blank" rel="noreferrer noopener">consensus estimate of $6.42 billion</a>.</li>
<li>Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter. However, it anticipates a 3% year-over-year increase in <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">core revenue for the full year of 2025</a>.</li>
<li>Following the earnings release, several analysts cut the price forecast on the stock, with Barclays analyst Luke Sergott lowering the price forecast from $275 to $240 and Wells Fargo analyst Brandon Couillard curtailing the price target from $280 to $240 and <a href="https://www.benzinga.com/25/01/43336758/danaher-analysts-cut-their-forecasts-after-downbeat-earnings" target="_blank" rel="noreferrer noopener">both maintaining an Equal-Weight</a>.</li>
<li>This month, Danaher raised quarterly dividend <a href="https://www.benzinga.com//node/43866316" target="_blank" rel="noreferrer noopener">per share from&nbsp;$0.27&nbsp;to&nbsp;$0.32</a>.</li>
</ul>
TMO Major Events:
<ul>
<li>Last month, the company reported fourth-quarter adjusted earnings per share of $6.10, beating the street view of $5.94 and sales of $11.395 billion (+5% year over year) outpaced the analyst <a href="https://www.benzinga.com/25/01/43337781/thermo-fisher-q4-earnings-beat-estimates-margin-expands" target="_blank" rel="noreferrer noopener">consensus estimate of $11.277 billion</a>.</li>
<li>Following the earnings release, several analysts raised the price forecast on the stock, with Morgan Stanley analyst Tejas Savant increasing the price target from&nbsp;$647&nbsp;to&nbsp;$678 and Wells Fargo analyst Brandon Couillard upped <a href="https://www.benzinga.com/quote/TMO/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from&nbsp;$660&nbsp;to&nbsp;$680</a>.</li>
<li>This month, Thermo Fisher Scientific raised its quarterly dividend<a href="https://www.benzinga.com//node/43830343" target="_blank" rel="noreferrer noopener"> from $0.39 to $0.43 per share</a>.</li>
<li>Thermo Fisher inked a 10-year VPPA with X-ELIO to enhance renewable energy access in pharmaceutical and healthcare supply chains through the Lorca solar project, set to launch <a href="https://www.benzinga.com/pressreleases/25/02/b43460138/thermo-fisher-scientific-accelerates-100-percent-renewable-electricity-goal-for-european-operation" target="_blank" rel="noreferrer noopener">in early 2026 with three industry partners</a>.</li>
</ul>
Year to date, Danaher shares declined around 10% while Thermo Fisher rose 0.66%, both underperforming the iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), which gained about 5%&nbsp;over the same time frame.
Also, the companies top peers Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) fell roughly 0.3% and IQVIA Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) declined about 1.3% so far this year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43796723/dan-loebs-third-point-boosts-meta-holdings-now-a-top-4-position" target="_blank" rel="noreferrer noopener">Dan Loeb&#8217;s Third Point Boosts Meta Holdings, Now A Top 4 Position</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

ETFs

iShares Trust Dow Jones US Healthcare Sector Index Fund

Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor

Investors with a lot of money to spend have taken a bullish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 53% bullish and 23%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $34,500, and 12, calls, for a total amount of $814,222.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $140.0 to $230.0 for Danaher during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Danaher's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale activity within a strike price range from $140.0 to $230.0 in the last 30 days. 
<h3>Danaher Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740170729_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$14.1</td>
<td>$14.1</td>
<td>$14.1</td>
<td>$210.00</td>
<td>$338.7K</td>
<td>468</td>
<td align="right">2</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$5.5</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$210.00</td>
<td>$103.8K</td>
<td>1.5K</td>
<td align="right">196</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$3.8</td>
<td>$3.5</td>
<td>$3.8</td>
<td>$212.50</td>
<td>$66.1K</td>
<td>719</td>
<td align="right">620</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$10.4</td>
<td>$9.3</td>
<td>$10.0</td>
<td>$210.00</td>
<td>$45.0K</td>
<td>933</td>
<td align="right">0</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$85.5</td>
<td>$84.4</td>
<td>$85.5</td>
<td>$140.00</td>
<td>$42.7K</td>
<td>6</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
In light of the recent options history for Danaher, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Danaher</h3>
<ul>
<li>With a trading volume of 3,978,641, the price of DHR is up by 1.46%, reaching $210.98.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 60 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Danaher</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $252.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Danaher with a target price of $240. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Danaher, which currently sits at a price target of $265. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on Danaher with a target price of $260. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $258. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Danaher, targeting a price of $240. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Danaher's Options Frenzy: What You Need to Know

Dividends

Danaher Increases Quarterly Dividend From $0.27 To $0.32

Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>)&nbsp;released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">but beating the consensus of 41 cents</a>.
The bioprocessing technology reported sales of $167.55 million, slightly up from $166.6 million a year ago, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43844804/repligen-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $167.67 million</a>.
Olivier Loeillot, President and Chief Executive Officer of Repligen, said, "During the fourth quarter, we were very encouraged by the continued momentum across our portfolio. Total revenue in the fourth quarter grew 13%, excluding COVID-19, overcoming two points of currency headwind. Total orders outpaced sales by 6%, driven by our Filtration and Analytics franchises&#8230;While we continue to monitor China and emerging biotech,&nbsp;the overall bioprocessing market is returning to growth. Our order momentum during the second half gives us confidence that we can achieve our 2025 guidance."
Guidance:&nbsp;Repligen expects 2025 sales of $685 million—$710 million, with organic growth of 9.5%—13.5% and non-COVID revenue growth of 10%—14% compared to the consensus of $694.86 million.
The company expects adjusted EPS of $1.67—$1.76 compared to the consensus of $1.73.
William Blair says Repligen's Q4 results and 2025 outlook confirm that the bioprocessing industry is recovering strongly, with growth expected to return to normal levels next year.
Repligen's guidance reflects strong quarterly momentum, signaling a market recovery.
Compared to peers like Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) and Avantor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NASDAQ">AVTR</a>), which project mid-to-high single-digit growth in bioprocessing, Repligen's outlook highlights its strong product portfolio and customer positioning that have driven consistent above-market growth.
Since Repligen focuses solely on bioprocessing and has minimal exposure to risks in NIH-funded research, academia, or China, analyst Matt Larew believes its guidance is more predictable than competitors with broader market and geographic exposure.
Price Action: RGEN stock is up 8.16% at $163.03 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43853635/hf-sinclair-reports-mixed-q4-results-with-weak-earning-weak-refining-margins-drive-93-drop-in-adjusted-ebitda" target="_blank" rel="noreferrer noopener">HF Sinclair Reports Mixed Q4 Results, Weak Refining Margins Drive 93% Drop In Adjusted EBITDA</a></li>
</ul>
Image via Repligen

Analyst Color

Earnings

Guidance

Health Care

Analyst Ratings

Movers

General

AVTR

RGEN

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

In the current session, Danaher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) is trading at $204.95, after a 0.01% decrease. Over the past month, the stock decreased by 16.56%, and in the past year, by 19.25%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1740056425_0.png" alt="Past Year Chart" />

<h3>A Look at Danaher P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 95.78 in the Life Sciences Tools &amp; Services industry, Danaher Inc. has a lower P/E ratio of 38.75. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740056425_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Danaher

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$77.50</td>
<td>$27.5K</td>
<td>206</td>
<td>6.0K</td>
</tr>
<tr>
<td>EYPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.00</td>
<td>$49.7K</td>
<td>431</td>
<td>1.0K</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$100.00</td>
<td>$37.1K</td>
<td>475</td>
<td>384</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$108.00</td>
<td>$38.3K</td>
<td>45</td>
<td>339</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$162.5K</td>
<td>3.5K</td>
<td>222</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$110.4K</td>
<td>5.0K</td>
<td>183</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$240.00</td>
<td>$28.4K</td>
<td>5</td>
<td>136</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$257.3K</td>
<td>1.3K</td>
<td>134</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$200.00</td>
<td>$106.5K</td>
<td>203</td>
<td>95</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$550.00</td>
<td>$171.4K</td>
<td>710</td>
<td>66</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 62 contract(s) at a $77.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.5K, with a price of $445.0 per contract. There were 206 open contracts at this strike prior to today, and today 6063 contract(s) were bought and sold. 
• For EYPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>), we notice a put option sweep that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $5.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $49.7K, with a price of $95.0 per contract. There were 431 open contracts at this strike prior to today, and today 1002 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a call option sweep that happens to be bearish, expiring in 304 day(s) on December 19, 2025. This event was a transfer of 24 contract(s) at a $100.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $37.1K, with a price of $1553.0 per contract. There were 475 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on March 7, 2025. This event was a transfer of 276 contract(s) at a $108.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $38.3K, with a price of $139.0 per contract. There were 45 open contracts at this strike prior to today, and today 339 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $162.5K, with a price of $3250.0 per contract. There were 3527 open contracts at this strike prior to today, and today 222 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 96 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $110.4K, with a price of $1150.0 per contract. There were 5079 open contracts at this strike prior to today, and today 183 contract(s) were bought and sold. 
• Regarding WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 16 contract(s) at a $240.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.4K, with a price of $1780.0 per contract. There were 5 open contracts at this strike prior to today, and today 136 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option sweep with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 83 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $257.3K, with a price of $3100.0 per contract. There were 1316 open contracts at this strike prior to today, and today 134 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 82 contract(s) at a $200.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1300.0 per contract. There were 203 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 40 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $171.4K, with a price of $4285.0 per contract. There were 710 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EYPT

GILD

TMDX

10 Health Care Stocks Whale Activity In Today's Session

Deep-pocketed investors have adopted a bearish approach towards Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DHR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for Danaher. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 26% leaning bullish and 56% bearish. Among these notable options, 20 are puts, totaling $644,075, and 3 are calls, amounting to $143,154.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $202.5 to $230.0 for Danaher over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Danaher's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale trades within a strike price range from $202.5 to $230.0 in the last 30 days. 
<h3>Danaher Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739380528_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.3</td>
<td>$2.7</td>
<td>$2.7</td>
<td>$202.50</td>
<td>$63.4K</td>
<td>79</td>
<td align="right">410</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$8.2</td>
<td>$7.8</td>
<td>$8.0</td>
<td>$210.00</td>
<td>$44.8K</td>
<td>246</td>
<td align="right">61</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$31.0</td>
<td>$30.6</td>
<td>$30.87</td>
<td>$230.00</td>
<td>$40.0K</td>
<td>1.6K</td>
<td align="right">103</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$31.0</td>
<td>$30.6</td>
<td>$30.87</td>
<td>$230.00</td>
<td>$40.0K</td>
<td>1.6K</td>
<td align="right">107</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$30.8</td>
<td>$30.4</td>
<td>$30.6</td>
<td>$230.00</td>
<td>$36.7K</td>
<td>1.6K</td>
<td align="right">674</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Following our analysis of the options activities associated with Danaher, we pivot to a closer look at the company's own performance.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,166,471, with DHR's price down by -0.72%, positioned at $200.16.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>What The Experts Say On Danaher</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $258.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Danaher, maintaining a target price of $240. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $277. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Danaher, maintaining a target price of $260. 
&#x2A; An analyst from Raymond James has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $275. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Danaher, maintaining a target price of $240. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Danaher options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Investors with a lot of money to spend have taken a bullish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $110,000, and 7, calls, for a total amount of $1,494,500.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $230.0 for Danaher, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Danaher's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale activity within a strike price range from $120.0 to $230.0 in the last 30 days. 
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738957522_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.4</td>
<td>$13.1</td>
<td>$13.3</td>
<td>$220.00</td>
<td>$997.5K</td>
<td align="right">69</td>
<td>1.0K</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.3</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$220.00</td>
<td>$336.5K</td>
<td align="right">69</td>
<td>5</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$22.6</td>
<td>$21.2</td>
<td>$22.0</td>
<td>$230.00</td>
<td>$110.0K</td>
<td align="right">389</td>
<td>52</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.8</td>
<td>$5.6</td>
<td>$5.64</td>
<td>$210.00</td>
<td>$45.0K</td>
<td align="right">683</td>
<td>132</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$12.9</td>
<td>$12.8</td>
<td>$12.9</td>
<td>$210.00</td>
<td>$32.2K</td>
<td align="right">92</td>
<td>47</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Following our analysis of the options activities associated with Danaher, we pivot to a closer look at the company's own performance.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,853,407, the DHR's price is down by -0.06%, now at $209.89. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 74 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Danaher Unusual Options Activity For February 07

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he likes NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) and recommended buying the same. &#8220;I think you've got a <a href="https://www.benzinga.com/quote/NEE/earnings">good one,&#8221; he added</a>.
On Jan. 24, NextEra Energy Inc posted in-line earnings for the fourth quarter and said it continues to expect adjusted EPS of $3.45-$3.70 for FY25.
<h3 class="wp-block-heading">Cramer&#8217;s Take On Tech Stocks</h3>
<ul>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) has missed the quarter too often, Cramer said. &#8220;If you want to be in that, you want to be in Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>).&#8221; The San Francisco-based company will release financial results for the fourth quarter after the closing bell on Wednesday, Feb. 12.</li>
<li>A10 Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) is &#8220;up in a straight line, it's a parabolic move.&#8221; He noted that although it's a good company, but he can't recommend parabolic stocks. &#8220;Let that one come in,&#8221; he added. The San Jose, California-based company, on Feb. 4, posted better-than-expected earnings for its fourth quarter.</li>
</ul>
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has been bad for him, the Mad Money host said. &#8220;That last quarter was terrible, and, frankly, they were very smug on the call talking about how good it was, and that was a very ill-advised strategy that they adopted, and I don't like it.&#8221;
Supporting his view, Raymond James analyst Andrew Cooper, on Feb. 3, downgraded Danaher from Outperform to Market Perform.
IES Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) is Jeffrey Gendell's [Chief Executive Officer for IES Holdings] company, Cramer said. &#8220;He is a, just an amazing man.&#8221;
As per the recent earnings report, IES, on Tuesday, reported quarterly earnings of $2.64 per share, up from $1.86 per share from the same period last year. The company reported $749.50 million in sales during the quarter, compared to $634.40 million the same period last year.
Cramer said Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is a &#8220;really great&#8221; company, but he doesn't want to recommend the stock. &#8220;It's the best house in a bad neighborhood, and we don't want to be in bad neighborhoods,&#8221; he added.
In the recent news, Schlumberger's OneSubsea joint venture on Tuesday entered an agreement with Vår Energi to deliver a subsea production systems work scope, aimed at supporting multiple upcoming oil and gas developments on the Norwegian Continental Shelf.
Price Action:
<ul>
<li>NextEra Energy shares gained 0.1% to settle at $69.27 on Thursday.</li>
<li>Fastly shares dipped 2.4% to close at $9.99 during the session.</li>
<li>Danaher shares fell 1% to settle at $210.01.</li>
<li>IES shares climbed 8.4% to close at $242.10 on Thursday.</li>
<li>SLB shares fell 1.9% to settle at $40.05.</li>
<li>A10 Networks shares fell 1.3% to close at $20.55 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43536198/top-2-industrials-stocks-that-are-ticking-portfolio-bombs">Top 2 Industrials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Jim Cramer Likes This Utilities Stock: 'I Think You've Got A Good One'

High-rolling investors have positioned themselves bullish on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in DHR often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 13 options trades for Danaher. This is not a typical pattern.
The sentiment among these major traders is split, with 61% bullish and 38% bearish. Among all the options we identified, there was one put, amounting to $26,400, and 12 calls, totaling $9,798,273.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $220.0 and $240.0 for Danaher, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Danaher stands at 1815.33, with a total volume reaching 6,881.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Danaher, situated within the strike price corridor from $220.0 to $240.0, throughout the last 30 days.
<h3>Danaher Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738607423_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$28.6</td>
<td>$27.3</td>
<td>$28.6</td>
<td>$240.00</td>
<td>$7.8M</td>
<td>2.5K</td>
<td>3.4K</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$30.1</td>
<td>$26.5</td>
<td>$29.9</td>
<td>$240.00</td>
<td>$299.0K</td>
<td>2.5K</td>
<td>0</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.6</td>
<td>$27.4</td>
<td>$29.6</td>
<td>$240.00</td>
<td>$296.0K</td>
<td>2.5K</td>
<td>300</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.4</td>
<td>$28.3</td>
<td>$29.4</td>
<td>$240.00</td>
<td>$294.0K</td>
<td>2.5K</td>
<td>630</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.4</td>
<td>$28.2</td>
<td>$29.4</td>
<td>$240.00</td>
<td>$294.0K</td>
<td>2.5K</td>
<td>510</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Danaher</h3>
<ul>
<li>Currently trading with a volume of 2,405,344, the DHR's price is down by -2.51%, now at $217.16. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 78 days.</li>
</ul>
<h3>Professional Analyst Ratings for Danaher</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $256.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Danaher, maintaining a target price of $260. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $258. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Danaher with a target price of $240. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Danaher, which currently sits at a price target of $240. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Danaher, maintaining a target price of $285. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Danaher's Options: A Look at What the Big Money is Thinking

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst Andrew Cooper downgraded the rating for Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Outperform to Market Perform. Danaher shares closed at $222.74 on Friday. <a href="https://www.benzinga.com/quote/DHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Rick Paterson downgraded FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from Buy to Hold and lowered the price target from $365 to $283. FedEx shares closed at $264.87 on Friday. <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Shrenik Kothari downgraded CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from Outperform to Neutral but raised the price target from $390 to $430. CrowdStrike shares closed at $398.07 on Friday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Michael Lavery downgraded the rating for Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from Overweight to Neutral and lowered the price target from $245 to $200. Constellation Brands shares closed at $180.80 on Friday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Carlos De Alba downgraded United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) from Overweight to Equal-Weight and maintained the price target of $39. United States Steel shares closed at $36.85 on Friday. <a href="https://www.benzinga.com/quote/X/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying FDX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="527" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3-1024x527.png" alt="" class="wp-image-762952" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3-1024x527.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03111928/image-3.png 1091w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Downgrades

CRWD

This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Raymond James analyst Andrew Cooper downgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Outperform to Market Perform.

Raymond James Downgrades Danaher to Market Perform

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

Price Target

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 3.19% on an annualized basis producing an average annual return of 14.69%. Currently, Danaher has a market capitalization of $160.47 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $390.71 today based on a price of $223.16 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738269014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years

RBC Capital analyst Conor McNamara reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $299 to $277.

Reiteration

RBC Capital Reiterates Outperform on Danaher, Lowers Price Target to $277

Baird analyst Catherine Schulte maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $268 to $258.

Baird Maintains Outperform on Danaher, Lowers Price Target to $258

Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported weaker-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/dhr/earnings">earnings on Wednesday</a>.
The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.
The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.
Rainer M. Blair, President and Chief Executive Officer, stated, "Good execution by our team also drove solid cash flow and operating margin expansion."
Danaher said it expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter. However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.
Danaher shares fell 9.7% to close at $223.73 on Wednesday.
These analysts made changes to their price targets on Danaher following earnings announcement.
<ul>
<li>Barclays analyst Luke Sergott maintained Danaher with an Equal-Weight and lowered the price target from $275 to $240.</li>
<li>Wells Fargo analyst Brandon Couillard maintained Danaher with an Equal-Weight and cut the price target from $280 to $240.</li>
</ul>
Considering buying DHR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-1024x578.png" alt="" class="wp-image-758143" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261.png 1120w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a></li>
</ul>

Danaher Analysts Cut Their Forecasts After Downbeat Earnings

Wells Fargo analyst Brandon Couillard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Equal-Weight and lowers the price target from $280 to $240.

Wells Fargo Maintains Equal-Weight on Danaher, Lowers Price Target to $240

Press Releases

Danaher CEO to Comment on Financial Performance

Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research

Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications

Compass Minerals Announces Senior Leadership Team Appointments

Danaher Reports Fourth Quarter and Full Year 2024 Results

TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

Danaher Increases Quarterly Dividend

Danaher Announces Appointment of Charles Lamanna to Danaher Board

Danaher to Present at TD Cowen Health Care Conference

Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System

MRVI

MSFT

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Danaher

Noticias

Últimas noticias sobre Danaher (NYSE:DHR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL